Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aegera Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Aegera Therapeutics Inc. was formed in May 2000 through the merger of Apoptogen Inc. and Exogen Neurosciences Inc. Aegera will build on the neural signal transduction and apoptosis platforms of its founding companies with a goal of discovering and developing therapeutics for neurodegenerative diseases, peripheral neuropathies and cancer.

Related Content

New Approaches for Neurodegenerative Disorders


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts